Biocartis Group NV: Biocartis announces financial calendar 2016

Mechelen, Belgium, 16 December 2015: Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces its financial calendar for 2016.

• 17 March 2016 - Full Year Results 2015 and guidance for 2016.
• 17 March 2016 - Capital Markets Day tailored for institutional investors, research analysts and sector journalists.
• 12 April 2016 - Publication of the Annual Report for the year 2015.
• 12 May 2016 - Q1 2016 Business Update and Quarterly Results.
• 13 May 2016 - Annual General Meeting 2016.
• 6 September 2016 - Half year results H1 2016.
• 17 November 2016 - Q3 Business Update 2016 and Quarterly Results.

----- END -----

For more information:

Renate Degrave (Corporate Communications & Investor Relations)

+32 15 632 600

press@biocartis.com

Consilium Strategic Communications

Amber Fennell, Jessica Hodgson, Chris Welsh, Hendrik Thys

+44 (0) 203 709 5701 (London, UK)

biocartis@consilium-comms.com    

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla(TM) addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis launched the Idylla(TM) platform commercially in September 2014 together with its first test to identify BRAF mutations in metastatic melanoma. In June 2015, the Idylla(TM) KRAS Mutation Test for colorectal cancer was launched, followed by the first infectious disease test in November 2015, the Idylla(TM) Respiratory (IFV-RSV) Panel, developed in collaboration with Janssen Diagnostics. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. More information: www.biocartis.com.